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ABSTRACT
Uncovering novel growth modulators for non-small cell lung cancer (NSCLC) may 
lead to new therapies for these patients. Previous studies suggest Nit1 suppresses 
chemically induced carcinogenesis of the foregut in a mouse model. In this study we 
aimed to determine the role of Nit1 in a transgenic mouse lung cancer model driven 
by a G12D Kras mutation. Nit1 knockout mice (Nit1−/−) were crossed with KrasG12D/+ 
mice to investigate whether a G12D Kras mutation and Nit1 inactivation interact to 
promote or inhibit the development of NSCLC. We found that lung tumorigenesis 
was suppressed in the Nit1-null background (Nit1−/−:KrasG12D/+). Micro-CT scans and 
gross tumor measurements demonstrated a 5-fold reduction in total tumor volumes 
compared to Nit1+/+KrasG12D/+ (p<0.01). Furthermore, we found that Nit1 is highly 
expressed in human lung cancer tissues and cell lines and use of siRNA against Nit1 
decreased overall cell survival of lung cancer cells in culture. In addition, cisplatin 
response was enhanced in human lung cancer cells when Nit1 was knocked down and 
Nit1−/−:KrasG12D/+ tumors showed increased sensitivity to cisplatin in vivo. Together, 
our data indicate that Nit1 may play a supportive role in the modulation of lung 
tumorigenesis and represent a novel target for NSCLCs treatment.
INTRODUCTION
Lung cancer is the leading cause of cancer 
mortality worldwide [1, 2]. It generally presents with 
genomic instability and abnormalities that researchers 
have exploited as novel sources for targeted therapeutics 
[3, 4]. The success of these research efforts in utilizing 
targeted therapeutics has aided clinicians in the 
management of lung cancer patients [5–7]. Non-small 
cell lung cancers (NSCLCs), which represent 85% of all 
lung cancers, generally present at very advanced stages 
requiring intensive and multimodal treatments [8]. Kras 
mutations, present in about 20-30% of NSCLCs, lead to 
the over activation of the mitogen-activated protein kinase 
(MAPK) pathway, which has diverse impacts on cellular 
proliferation [9]. Mutations in the Kras pathway have 
continually led cancer patients to decreased responses to 
chemotherapeutics and radiation therapy treatments [10]. 
The overall decreased response rates due to activating 
mutations in NSCLCs make it critically important to find 
new targets.
Galperin and Koonin listed the ‘top 10’ attractive 
targets with the expectation that characterization of these 
conserved proteins would reveal new aspects of biology. 
The fourth entry in the ‘top 10’ table was Nitrilase 1 
(Nit1), a gene conserved from bacteria, yeast, plants, 
insects, invertebrates to vertebrates and mammals [11].
The nitrilase superfamily consists of thiol enzymes 
involved in natural product biosynthesis and post-
translational modification in plants, animals, fungi and 
prokaryotes. 9/13 branches have known or deduced 
specificity for specific nitrile- or amide-hydrolysis or 
amide-condensation reactions [12]. In Arabidopsis, there 
are four nitrilases (Nitrilase 1–4), of which Nit1 shows 
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the highest homology to animal and bacterial nitrilases. 
It was found that in plants, Nit1 is required to repress 
proliferation and in its absence causes cells to become 
polyploidy due to defects that occur in cytokinesis [13]. 
All mammalian species contain Nit1 genes, which share 
~40% sequence homology; however, the substrate of 
Nit1 still has not been discovered. Recent studies of Nit1 
have begun to indicate its potential role in tumorigenesis. 
Although Nit1-deficient mice have a normal life cycle, 
reproduction, and do not develop spontaneous tumors, 
they are more sensitive to carcinogen-induced forestomach 
tumors [14, 15]; in addition, ectopic expression of Nit1 
leads to caspase activation and apoptosis, and may play 
a role in DNA damage-induced apoptosis in cell models 
[14]. The culmination of these data led us to investigate 
the role that Nit1 may have in modulation of lung cancer.
RESULTS
Generation and identification of the Nit1−/− 
KrasG12D/+ mouse lung cancer model
To investigate the impact of Nit1 on lung 
carcinogenesis and progression, we crossed Nit1−/− mice 
with KrasG12D/+ spontaneous lung adenocarcinomas mice as 
outlined in Figure 1A. PCR-based genotyping established 
the genetic status of Nit1 and KrasG12D and Western blots 
of lung tissue lysate confirmed the deficiency of Nit1 
protein as shown in Figure 1B. Immunohistochemistry 
also demonstrated a lack of Nit1 expression in knockout 
strains in both tumor and the surrounding lung tissues, 
while positive staining of Nit1 can be found in the nucleus 
and cytoplasm of wild-type mice lung tissue cells (Figure 
1C), which is consistent with Huebner’s data [14] and the 
Human Protein Atlas (HPA) Nit1 datasets [http://www.
proteinatlas.org/ENSG00000158793-NIT1/tissue/lung].
Tumor burden and survival proportion of Nit1 
deficient KrasG12D/+ mouse lung cancer model
To determine the lung tumor burden of 
Nit1+/+:KrasG12D/+ vs. Nit1−/−:KrasG12D/+, mice were 
sacrificed when they reached 4-6 months of age. Tumor 
burden was measured through a number of approaches. 
First, we counted and graphed the lung tumor nodules 
at the pleural surface, and then nodules dissected from 
the tumor-bearing lungs bigger than 1mm in diameter 
were counted and graphed. As shown in Figure 2A and 
2B top, the number of pleural (p<0.001) or dissected 
tumor nodules (p<0.05) was significantly reduced in the 
Nit1−/−:KrasG12D/+ mice in comparison to Nit1+/+:KrasG12D/+ 
mice; in addition, the size of tumor nodules are much 
smaller in Nit1−/−:KrasG12D/+ mice (Figure 2A, 2B middle). 
Next, we measured the weight of tumor-bearing lungs as 
well as dissected tumors from mice of the two genotypes 
and demonstrated that Nit1+/+:KrasG12D/+ mice have a 
heavier tumor load. Because micro-CT is an effective 
tool to noninvasively measure the growth of primary 
lung cancers and assess the tumor therapeutic response 
in genetically engineered mice [16], we contoured the 
tumor nodules and calculated tumor volumes through the 
3D reconstructed micro-CT images using MIM software 
(Cleveland, OH, USA) [17]. As shown in Figure 2C, 
Nit1−/−:KrasG12D/+ mice have fewer and smaller lung lesions 
on CT with a 5-fold reduction of total tumor volume 
(median) compared with Nit1+/+:KrasG12D/+ mice (Figure 
2D, p<0.01). Figure 2E shows the effect of Nit1 deficiency 
on survival of KrasG12D/+ mice. Remarkably, Nit1 deficient 
mice have a trend to live longer (Log-rank test for trend, 
▲ P<0.05) though the median survival has no difference 
in Nit1+/−:KrasG12D/+ vs Nit1+/+:KrasG12D/+, however, 
Nit1−/−:KrasG12D/+ mice have significantly elongated life 
spans when compared with wild-type controls (Mantel-
Cox test, * P<0.05).
Reduced tumor lesions in Nit1 deficient 
KrasG12D/+ mice
H&E staining of Nit1+/+:KrasG12D/+ vs. 
Nit1−/−:KrasG12D/+ mice lung lesions were analyzed by a 
pathologist who specializes in lung cancer. These lung 
lesions obtained from both groups were pathologically 
indistinguishable adenocarcinoma (Figure 3B left) 
and the final tumor incidences of both genotypes are 
similar (100% at 4-6 months old). Cross-sections of 
tumor-bearing lungs following H&E staining showed 
Nit1−/−:KrasG12D/+ mice have decreased tumor area (Figure 
3A, 3C top) and or decreased tumor number (Figure 
3A, 3C middle) compared with wild-type controls. 
IHC staining of proliferation marker Ki67 indicated 
that tumor proliferation was suppressed significantly in 
Nit1−/−:KrasG12D/+ mice (Figure 3B, 3C bottom).
Increased NIT1 expression in human lung cancer
Western blots confirmed Nit1 expression in 
immortalized human bronchial epithelial cells and 
multiple human NSCLCs cell lines (Figure 4A). We 
then performed immunohistochemistry staining on a 
human lung cancer tissues (TMA) slide. Representative 
examples of IHC for Nit1 in squamous cell carcinoma and 
adenocarcinoma were shown in Figure 4B lower panels. 
In the 5/10 non-malignant lung tissues (from patients 
with non-malignant lung diseases), weakly Nit1 staining 
(expression score ~0.6) can be identified within the 
pneumocytes and macrophages (Figure 4B top, 4C lower). 
However, positive staining of Nit1 in lung cancer cells is 
more prevalent especially in squamous cell carcinoma 
(97.5%, Figure 4B middle, 4C upper) and adenocarcinoma 
(97.7%, Figure 4B bottom, 4C upper). Quantitation of 
the Nit1 staining amongst distinct human lung tumors 
demonstrated an approximately 2-fold increase of Nit1 
Oncotarget21383www.impactjournals.com/oncotarget
staining intensity in squamous cell carcinoma (p<0.01) 
and 3-fold increase in adenocarcinoma (p<0.0001) over 
non-malignant lung tissues (Figure 4C lower).
Nit1 knockdown decreases survival of multiple 
human lung cancer cell lines
To determine whether lung cancer is dependent upon 
a high level of Nit1 expression, we tested lung cancer 
cell survival following Nit1 knockdown through siRNA 
using a specific siRNA smart pool. BLAST searches 
and scramble siRNA pools that do not match any known 
mammalian GENEBANK sequences determined the 
sequence specificity. In addition, we used siRNA against 
Nit2 as a gene control because Nit2, like Nit1, belongs 
to the nitrilase superfamily and structurally clustered 
with Nit1 in Arabidopsis which shares 55% homology 
of Nit1 [18]. Knocking down of Nit1 or Nit2 in A549 
lung cancer cells were validated by Western blotting as 
shown in the lower panel of Figure 5A. The upper panel 
of Figure 5A demonstrates that the survival reduction of 
most of the tested lung cancer cell lines is only observed 
in cells transfected with siRNA against Nit1, but not in 
cells transfected with control siRNA or siRNA against 
Nit2. To further confirm that the survival reduction was 
due to Nit1 knockdown specifically, Nit1 overexpressing 
adenovirus was used to restore Nit1 level post knockdown. 
Quantitative PCR and Western blot analysis confirmed that 
Nit1 mRNA and protein levels were decreased after Nit1 
siRNA and then restored to a higher level compared with 
adenovirus GFP control groups. Cell survival was rescued 
upon Nit1 overexpression, which implies that reduction 
of lung cancer survival depends on Nit1 level, as shown 
in Figure 5B.
Nit1 deficiency enhances therapeutic effect of 
cisplatin to NSCLCs
To determine the impact of Nit1 in mediating 
therapeutic effects against lung cancer, we knocked 
down Nit1 through siRNA and followed with cisplatin 
treatment on the relatively cisplatin resistant human 
Figure 1: Generation and identification of the Nit1−/−:KrasG12D/+ mouse lung cancer model. A. Mouse breeding strategy. 
B. Mouse genotyping and western blot of Nit1 in F2 mice of various genotypes. Nit1 was highly expressed in wild-type and human lung 
cancer cell line (A549), lower expressed in Nit1+/- KrasG12D/+ and absent in Nit1-/- KrasG12D/+ mouse, actin expression was also analyzed as a 
control. C. Immunohistochemistry of Nit1 in mouse lung tissue sections from two genotypes. There is no signal of Nit1 in Nit1-/-:KrasG12D/+ 
mouse (lower panel) while Nit1 is positive in Nit1+/+:KrasG12D/+ mouse lung tissue (top panel). High magnification of tumor (orange) and 
normal (black) lung tissues was photographed.
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lung cancer cell line A549. As shown in Figure 6A, 
there was no significant decrease in cell survival after 
cisplatin treatment in Nit1 wild type (100% vs. 90%, 
p>0.05, left blue bars), while it was significantly 
decreased with Nit1 knockdown (60% vs. 40%, 
p<0.05, red bars). And the cisplatin response after Nit1 
knockdown was remarkably increased (p<0.05, Figure 
6A right). Reductions in cell survival indicate that 
Nit1 deficiency might sensitize cisplatin response in 
human lung cancer. To confirm this finding in vivo, we 
compared the cisplatin responses in Nit1−/−:KrasG12D/+ 
mice with their wild-type counterpart, since KrasG12D/+ 
Figure 2: Tumor burden and survival proportion of Nit1 deficient KrasG12D/+ mouse lung cancer model. A. Representative 
images of 6 months old mice lung tumor burden. Left: Ink staining showing tumor nodules at the pleural surface. Right: tumor nodules 
dissected from tumor-bearing lungs. B. Statistical analysis of number of all pleural tumor nodules (top left) or dissected tumors (top right); 
size distribution of pleural tumor nodules (>3mm vs. <3mm) (mid left), dissected tumor nodules (mid right). Each dot/triangle in these 
two plots represents total tumors of one mouse, instead of a tumor sample. The x y co-ordinates show the number of surface/dissected 
nodules diameter D> 3mm (horizontal) and the number of D< 3mm (vertical) of each mouse; weight of tumor-bearing lungs (bottom left) 
or dissected tumors (bottom right) from Nit1+/+:KrasG12D/+ (WT) or Nit1-/-:KrasG12D/+ (KO) mice. Mann Whitney test, * P<0.05, ** P<0.01, 
*** P<0.001; n: number of mice. C. Representative micro-CT image. Left: Axial CT images, tumor area are marked with red circles; 
Right: color-rendered 3D representations of tumor volumes from coronal and sagittal planes. D. Statistical analysis of tumor volumes 
measured through micro-CT. Mann Whitney test, ** P<0.01. E. Survival proportions of Nit1 deficient KrasG12D/+ mice models. Log-rank 
(Mantel-Cox) test for survival curves * P<0.05, and Log- rank test for trend ▲ P<0.05.
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mice easily acquire cisplatin resistance. Before 
and after 4 doses of cisplatin treatment at 7.5 mg/
kg every 3 days, tumor volumes were measured by 
the micro-CT. All tumor-bearing Nit1−/−:KrasG12D/+ 
mice demonstrated tumor shrinkage, whereas more 
than half of the Nit1 wild-type group had persistent 
tumor growth as shown by the waterfall plot (Figure 
6C). Representative CT images of tumor volume 
increasing in Nit1+/+:KrasG12D/+ mice (purple arrows), 
while decreasing in Nit1−/−:KrasG12D/+ mice (red arrows) 
were shown in Figure 6B. The observed difference is 
statistically significant (p<0.01 Figure 6C).
DISCUSSION
Increasing knowledge of activating driver mutations 
in NSCLCs has prompted the development of various 
targeted therapeutics [19, 20]. Studies have indicated 
that activating mutations such as Kras mutations are poor 
prognostic indicators and predictors for poor response to 
standard therapies [7, 21–23]. Based on these findings, it 
is clear that novel therapeutic targets are urgently needed 
to improve tumor sensitivities.
Nit1 was initially identified as a gene fused to 
Fhit in Drosophila melanogaster and Caenorhabditis 
Figure 3: Reduced tumor lesions in Nit1 deficient KrasG12D/+ mice. A. Representative H&E whole-slide scan images shown tumor 
number and area difference. B. Representative pathologic micrographs of the lung tumor lesions by H&E (left) and Ki67 IHC staining 
(right). Orange rectangle is the higher magnification of lower magnification (black) lung tumor area. C. Statistical analysis of tumor lesions 
in three sections from each mouse (identical levels, mean values) , tumor area (top), number of total nodules (middle) and Ki67-positive 
cells (bottom) in similar size tumors, Mann Whitney test, * P<0.05, ** P<0.01.
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elegans [24]. Based on the ‘Rosetta stone’ hypothesis 
[25], previous studies predicted Fhit and Nit1 would 
function in the same pathway in mammals and described 
Nit1 as possessing tumor suppressor characteristics in 
mice forestomach tissue and additive to gene FHIT [15]. 
However, the physical interaction between Fhit and 
Nit1, which are located on two different chromosomes 
in mammals, has not been confirmed [26]. In addition, 
Figure 4: Increased Nit1 expression in human lung cancer. A. Nit1 expression in human immortalized bronchial epithelia 
(16HBE) and NSCLCs cell lines. B. Representative examples of IHC staining of Nit1 in non-malignant lung tissue and tumors as indicated. 
Higher magnification of orange rectangle area in the lower magnification black rectangle is shown as background image. C. IHC staining 
of Nit1 in lung cancer samples was quantitated for percentage of positive Nit1 staining and their expression scores for each subtype of lung 
cancer. Data is shown as mean ±SEM for Nit1 expression score, Mann Whitney test, * P<0.05, ** P<0.01, **** P<0.0001.
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web-databases (GeneCards, Ensembl et al.) show NIT1 
copy number and mRNA levels are increased in human 
lung cancer samples compared with normal tissue, while 
there is no FHIT protein expression in human (Oncomine, 
COSMIC) or mouse lung tissue [14]. All these information 
suggest that gene NIT1 may function independently and 
may not be suppressor in human lung cancer.
To investigate whether Nit1 deficiency may promote 
or inhibit the development of NSCLCs, we knocked out 
Nit1 in KrasG12D/+ mice lung cancer model background 
(Figure 1). Surprisingly, Nit1−/−:KrasG12D/+ mice showed 
significantly decreased tumor burden (lesions, volume, 
lung and tumor weight) and significant life extension 
compared with Nit1+/+:KrasG12D/+ (Figure 2 and 3).
We confirmed Nit1 expression in multiple human 
NSCLCs cancer cells and investigated the relevance 
of Nit1 to human lung cancers through TMAs. The 
relative abundance of Nit1 was increased 2- to 3-fold in 
NSCLCs compared to non-malignant lung tissues, with 
adenocarcinomas having the highest Nit1 immune-staining 
intensity (Figure 4). Our findings are consistent with the 
datasets of Oncomine, so we further investigated lung 
cancer cell survival post gene NIT1 knock down. Our 
data showed that knocking down NIT1, but not NIT2, can 
decrease cell viability in various lung cancer cell lines, 
and that it can be rescued after NIT1 expression levels 
were restored with recombinant human Nit1 adenovirus. 
Increased Nit1 abundance in NSCLCs and Nit1 dependent 
lung cancer cell survival implied that the NIT1 gene could 
not be a suppressor in cultured human lung cancer cell 
lines. Based on our data and previous studies there appears 
to be an optimal level of Nit1 required for appropriate 
cellular proliferation. Either overexpression or knockdown 
could jeopardize the survival of cells; while their 
biological results might be depend on tissue or cell types.
Since gene mutations of the Kras pathway lead 
cancer patients to decreased responses to therapy 
treatments, we investigated the impact of Nit1 in mediating 
therapeutic effects against lung cancer. As shown in 
Figure 6A, significantly reduced cell survival post Nit1 
Figure 5: Nit1 knockdown decreases survival of multiple human lung cancer cell lines. A. Cell survival post Nit1/Nit2 
siRNA in multiple human lung cancer cell lines. Upper panel shown: Cell viability measured by MTS assay following various lung cancer 
cell lines transfected by control siRNA, siRNAs against Nit1 or Nit2, t-test, * P<0.05, ** P<0.01. Lower panel: western blot confirms 
knockdown of Nit1 or Nit2 by their siRNA in A549 cells. B. Nit1 siRNA knockdown with or without the rescue by Nit1-overexpressing 
adenovirus in A549 cells. Adenovirus MOI: 1:20, Incubation time: 72hr post siRNA transfection. Upper panel: Cell survival inhibition was 
rescued by over-expression of Nit1, in comparison to GFP overexpression (Ad-GFP), t-test, * P<0.05, ** P<0.01; middle panel: Relative 
expression level of Nit1 mRNA (normalized to mRNA level of GAPDH); Lower panel: western blot showing NIT1 protein level following 
transfection of Nit1 siRNA with or without Nit1-overexpressing adenovirus.
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knockdown combined with cisplatin treatment in resistant 
A549 indicated that Nit1 deficiency may sensitize cisplatin 
response in human lung cancer. Cisplatin treatment on 
KrasG12D/+ mice confirmed this finding in vivo. We 
tracked tumor nodules by the micro-CT before and after 
cisplatin treatment. The total tumor volume was decreased 
in some Nit1+/+:KrasG12D/+ mice, but more than half of them 
had persistent tumor growth, whereas all Nit1−/−:KrasG12D/+ 
mice demonstrated significant tumor shrinkage (Figure 
6B, 6C).
Despite the early descriptions of Nit1 potentially 
functioning like a tumor suppressor when overexpressed 
[14], our data showed that Nit1 knockdown could decrease 
cell viability in various lung cancer cell lines and lung 
tumorigenesis was significantly suppressed in Nit1 
knockout KrasG12D/+ mice. In addition, Nit1 knockdown 
has the ability to sensitize NSCLCs to cytotoxic agents 
(e.g. cisplatin). Based on these data, Nit1 may modulate 
growth patterns in lung cancer cells and maybe a new target 
for NSCLCs treatment in future. Similar to the results we 
demonstrated, Zheng et al. recently showed that knockdown 
of Nit2 in colon cancer produced decreased levels of 
cellular proliferation. Their data indicated that Nit2, a 
member of the nitrilase protein family, which also has been 
reported as a suppressor [27], acts as an oncogene in human 
colon cancer [28]. Together these data appear to implicate 
the nitrilase protein family as interesting targets for future 
research on tumorigenesis and mechanisms of action.
Figure 6: Nit1 deficiency enhances therapeutic effect of cisplatin to NSCLCs. A. Knockdown of Nit1 increases cisplatin response 
in A549 cells. MTS cell survival assay, 48h after 10μM cisplatin and post 24h after siRNA against Nit1. t-test, * P<0.05, ** P<0.01 B. Robust 
cisplatin response in KrasG12D/+ mice without Nit1. After 4 doses of cisplatin treatment at 7.5 mg/kg every 3 days, representative micro-CT axial 
images shown tumor growth in Nit1+/+:KrasG12D/+ mouse (left, purple arrows with yellow value of volumes); tumor vanished in Nit1-/-:KrasG12D/+ 
mouse (right, red arrows with yellow value of volumes). C. Statistical analysis of cisplatin response. Waterfall plot of total volume change 
before and after treatment (left), each bar represents one individual mouse; Relative volume change ratio or drug response (Right), each dot 
represents one individual mouse. Mann Whitney test, ** P=0.002. WT: Nit1+/+:KrasG12D/+; KO: Nit1-/-:KrasG12D/+.
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In the present study, we have shown the impact of 
knocking down Nit1 in vivo and in vitro in NSCLCs. We 
found reduced tumor lesions in Nit1 deficient KrasG12D/+ mice 
and then confirmed that human NSCLCs have high levels 
of Nit1. In addition, deficiency of Nit1 suppresses NSCLCs 
progression and sensitizes cisplatin treatment response. 
Continued work is focusing on two parts to elucidate the 
mechanism of Nit1 deficiency to suppress NSCLCs. One 
is the impact on apoptosis and cell cycle pathways in lung 
cancer cells, and the second is the interaction of the immune 
system and lung cancer cells as Nit1 has been reported as a 
negative regulator in primary T cells [29–31].
MATERIALS AND METHODS
Mouse models and genotyping protocols
All experiments were performed according to 
protocols approved by the Institutional Animal Care And 
Use Committee (IACUC) of Thomas Jefferson University 
and complied with the Guide for the Care and Use of 
Laboratory Animals. KrasG12D mutated mice were 
obtained from JAX (Strain Name: 129S/Sv-Krastm3Tyj/J 
Stock Number: 008185). They were maintained in a 
heterozygous state (KrasG12D/+) because homozygosity for 
the Kras LA2 allele is embryonically lethal as described 
[32]. The KrasG12D/+ mice were crossed with Nit1 knockout 
(Nit1−/−) mice, which were provided by Dr. Jianke Zhang 
[14, 15, 29] to generate Nit1+/−:KrasG12D/+ F1 mice. 
Nit1+/−:KrasG12D/+ were inbred to get F2 Nit1+/+:KrasG12D/+ 
and Nit1−/−:KrasG12D/+ mice, and then backcrossed to the 
Kras background through at least six generations.
Screening of founder animals and their 
offspring was performed by genomic PCR with 
the following primer sets: Nit1 wild-type allele, 
5′-GTTGGTCTAGCAATCTGTTATGA-3′ and 
5′-GTGCTGGGATTAAAGGTGTGC-3′; Nit1 deletion 
allele, 5′-GTACCGGATACCGATTACTTCGA-3′ and 
5′-GTGCTGGGATTAAAGGTGTGCA-3′; product 
length: Wild type = 310 bp, Mutant = 250 bp; Kras wild 
type allele, 5′-TGCACAGCTTAGTGAGACCC-3′ and 
5′-GACTGCTCTCTTTCACCTCC-3′; Kras mutant 
allele, 5′-TGCACAGCTTAGTGAGACCC -3′ and 
5′-GGAGCAAAGCTGCTATTGGC-3′; product length: 
Wild type = 220 bp, Mutant = 390 bp, Heterozygote = 220 
bp and 390 bp.
Western blot analysis
Resected tumor tissue and normal mice lung tissue 
were subject to a plastic micro tissue homogenizer and 
sonicated in T-PER tissue protein extraction reagent 
(Thermo Scientific) with protease and phosphatase 
inhibitor cocktail, while cultured cell were lysed with 
M-PER protein extraction reagent. Cell and tissue lysates 
were centrifuged at 9,000 × g for 10 minutes at 4°C. 
Supernatants were transferred to clean microcentrifuge 
tubes, frozen on dry ice, and thawed on ice. Total protein 
concentrations in the lysates were determined using 
BCA kit. Equal amount of total proteins (30μg/lane) 
were loaded on a 10% SDS-PAGE. Membranes were 
subsequently incubated with various primary antibodies.
Histologic analysis and immunohistochemistry
Tissue sections were cut at 5 μm and were stained 
with H&E or immunostained with rabbit anti-mouse Ki67 
(1:200; Santa Cruz), followed by the appropriate HRP-
conjugated secondary antibodies (1:200; Sigma) and 
Fast 3,3′-diaminobenzidine (DAB) chromogenic tablets 
(Sigma). Proliferation was quantified by the expression 
of Ki67 positive cells (3 images of same size tumors per 
lung) per microscopic field (×400). Lung and tumor area 
quantifications were carried out on H&E-stained slides. 
Pictures of each lung lobe were taken on a Nikon Eclipse 
90i microscope. Lung and tumor area were measured 
using NIS Elements 3.0 SP7 software (Nikon Instruments 
B.V. Europe). A lung cancer pathologist provided 
tumor grading and classification according to standard 
histopathological grading [33].
Characterization of mouse lung cancer
Paired littermates of F2 (Nit1+/+:KrasG12D/+ and 
Nit1−/−:KrasG12D/+) were sacrificed at different time points 
ranging from ages 4 to 7 months because these mice 
develop lung tumors as early as 1 week after birth and 
do not usually survive >200 days [32]. After preliminary 
analysis of F2 mice, we sacrificed 4-6 months old 
Nit1+/+:KrasG12D/+ and Nit1−/−:KrasG12D/+ mice that had 
been backcrossed to S129 background for representative 
analysis. The lung tissue was immediately removed after 
the mice were sacrificed and the tumor nodules visible 
on the lung surface were counted. Tumor diameter was 
measured with a caliper and tumors were divided into two 
groups: tumor diameter 0-3 mm (small nodules) and >3 
mm (large nodules). The left lungs containing tumors were 
fixed overnight in 10% neutral buffered formalin. The 
lungs were then transferred to 70% ethanol and processed 
for paraffin embedding. Tumor and normal tissue 
resections of right lung samples were used for protein and 
total RNA extraction.
Microcomputed tomography (micro-CT)
We chose 4-6 month old mice to anesthetize with a 
continuous flow of 1% to 3% isoflurane/oxygen mixture 
(2 L/min). Non-contrast whole body CT imaging without 
respiratory or cardiac gating was performed using the 
MicroCAT II small-animal CT scanner (Siemens ImTek 
Inc.) for approximately 10 min per mouse. X-rays are 
generated at 80 kVp and 500 μA. The resulting raw 
data were converted to the standard DICOM data sets 
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and imported to the MIM6.5 (MIM Software Inc.) for 
tumor contouring and 3D reconstruction. The image 
analysis method was based on using threshold and region-
grow algorithms to segment the image data and define 
the separate anatomic structures of interest. Volumes 
of interest were defined by manually drawing multi-
slice regions of interest on the tumor nodules (at 50% 
of maximum voxels) and the contralateral soft tissue. 
After the number and volume of nodules were contoured 
by MIM automatically, the tumor nodule structure was 
selected and rendered with a different color using the 
combination of manual segmentation and semi-automated 
contouring methods. These analyses were consistent 
between two independent operators and performed by a 
well-trained researcher in a blinded manner.
Quantitative real-time RT-PCR
Nit1 mRNA expression was confirmed by 
quantitative realtime RT-PCR. Total RNAs were amplified 
with OneStep RTPCR kit (Qiagen) and QuantiTest SYBR 
Green RT-PCR kit (Qiagen), using primers as follows: 
5′-GTACTTTGTACTCAGCCCAG- 3′ (forward) and 
5′-CCATAGAGGTCAGGTCTGCG-3′ (reverse). All 
real-time assays were carried out in triplicate using an 
Applied Biosystems 7900 HT real-time PCR platform 
(Life Technologies). The primer set for amplification of 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
mRNA served as a housekeeping control gene, and the 
levels of Nit1 transcripts were determined by the ΔΔCt 
method [34].
Tissue microarrays
Using an antibody from Sigma (HPA006657), 
immunohistochemical staining was conducted to detect 
Nit1 abundance in human lung cancer and normal tissue 
microarrays (BC01115b, US BioMax, http://www.
biomax.us/tissue-arrays/Lung/BC041115b) according 
to their standard protocol (http://www.biomax.us/pdfs/
ImmunohistochemistryStaining.pdf). The level of Nit1 
protein expression was categorized by a semi-quantitative 
score of the immunostaining intensity by light microscopy 
evaluation. We used a standard methodology that 
determined a range of staining intensities from negative 
to strong with intermediate grades. The intensity of 
immunoperoxidase staining was scored as 0 (negative), 1 
(minimal to low level of positive staining), 2 (moderate 
expression), or 3 (strong staining). Cores without clear 
tumor cells were excluded and the final subgroups 
included: 40 cases of lung squamous cell carcinoma (2 lung 
adenosquamous carcinomas), 44 lung adenocarcinoma, 4 
each of lung bronchioloalveolar carcinoma and large cell 
carcinoma, 6 small cell undifferentiated carcinoma, 5 
carcinoid, plus 10 non-malignant (normal) lung tissue. A 
pathologist evaluated and scored the cores of the tumors 
from the patients.
Cell culture, recombinant adenoviral vector, and 
siRNA
All human lung cancer cell lines were bought from 
ATCC and maintained in RMPI1640 supplemented with 
10% fetal bovine serum, 100-units/ml penicillin, and 
100µg/ml streptomycin (Gibico). Adenoviral recombinant 
human NIT1 was a gift from Dr. Kay Huebner [14]. 
All siRNAs targeted to ORF region were bought from 
Dharmacon and included NIT1 mixture smart pool (L-
020022-01-0005), NIT2 smart pool (L-017902-00-0005) 
and Non-targeting Pool (D-001810-10-20). MTS assay 
was used for cell viability test.
Statistical analysis
Data are presented as mean ± SEM. Prism6 software 
was used for comparison of lung tumor burden between 
same age Nit1+/+:KrasG12D/+ and Nit1−/−:KrasG12D/+ mice. A 
2-tailed Mann Whitney test was used unless stated otherwise 
and P value <0.05 was considered statistically significant.
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